JENNIFER ROZELLE: Open Payments
NPI 1043634181 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$339 in 15 payments from 7 companies in 2025. Trend: 2023 $370 · 2024 $520 · 2025 $339
Food & beverage: $339
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Alkermes, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
Products named: REXULTI, TRINTELLIX, CAPLYTA, ARISTADA, VIVITROL, UZEDY.
Industry payments across TX — which companies pay providers there.
